Abstracts tagged "giant cell arteritis"

Abstract Number: 9L • 2015 ACR/ARHP Annual Meeting
A Randomized Double-Blind Trial of Abatacept and Glucocorticoids for the Treatment of Giant Cell Arteritis
Carol A. Langford¹, David Cuthbertson², Steven R. Ytterberg³, Nader A. Khalidi⁴, Paul A. Monach⁵, Simon Carette⁶, Philip Seo⁷, Larry W. Moreland⁸, Michael Weisman⁹, Curry L. Koening¹⁰, Antoine G. Sreih¹¹, Robert F. Spiera¹², Carol McAlear¹³, Kenneth J. Warrington¹⁴, Christian Pagnoux⁶, Kathleen Maksimowicz-McKinnon¹⁵, Lindsy J. Forbess¹⁶, Gary S. Hoffman¹, Renee Borchin¹⁷, Jeffrey Krischer¹⁷ and Peter A. Merkel¹⁸, ¹Rheumatology, Cleveland Clinic, Cleveland, OH, ²Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, ³Rheumatology Division, Mayo Clinic, Rochester, MN, ⁴McMaster University, St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ⁵Rheumatology, Boston University School of Medicine, Boston, MA, ⁶Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁷Division of Rheumatology, Johns Hopkins, Baltimore, MD, ⁸Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁹Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁰Division of rheumatology, George E. Wahlen Department of Veterans Affairs Medical Center Salt Lake City and University of Utah, University of Utah School of Medicine, Salt Lake City, UT, ¹¹Department of Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹²Rheumatology, Hospital for Special Surgery, New York, NY, ¹³Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹⁴Rheumatology, Mayo Clinic, Rochester, MN, ¹⁵Rheumatology, University of Pittsburgh, Pittsburgh, PA, ¹⁶Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁷University of South Florida, Tampa, FL, ¹⁸Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Giant cell arteritis (GCA) is a large-vessel primary systemic vasculitis. Although glucocorticoids are effective in treating GCA, they are associated with substantial toxicity and…
Abstract Number: 1954 • 2015 ACR/ARHP Annual Meeting
How Can We Use Ultrasound in the Diagnosis and Management of Patients with Giant Cell Arteritis?
Cristina Ponte^1,2, Sophie Vaggers¹, Jan Sznajd¹, Lorraine O'Neill¹, Jennifer Piper³, Jessica Gunn¹, Kulveer Mankia¹ and Raashid Luqmani¹, ¹Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²Rheumatology and Metabolic Bone Diseases Department, Rheumatology Research Unit - IMM, Lisbon Academic Medical Centre, Lisbon, Portugal, ³Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom
Background/Purpose: Giant cell arteritis (GCA), the most common primary vasculitis, can cause irreversible blindness in 20-30% of untreated cases, but glucocorticoid therapy leads to significant…
Abstract Number: 2161 • 2015 ACR/ARHP Annual Meeting
Ustekinumab for the Treatment of Refractory Giant Cell Arteritis
Richard Conway^1,2, Lorraine O'Neill^3,4, Eileen O'Flynn³, Geraldine M. McCarthy^5,6, Conor Murphy⁷, Douglas J. Veale⁸, Ursula Fearon⁹ and Eamonn S. Molloy¹⁰, ¹CARD Newman Research Fellow, University College Dublin, Dublin, Ireland, ²Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, University College Dublin, Dublin, Ireland, ³Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ⁴Rheumatology, St. Vincent's University Hospital, Dublin 4, Ireland, ⁵Rheumatology, Mater Misericordiae University Hospital, Dublin 7, Ireland, ⁶University College Dublin, Dublin, Ireland, ⁷Department of Ophthalmology, Royal Victoria Eye and Ear Hospital, Dublin, Ireland, ⁸St Vincent's University Hospital, Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, Dublin 4, Ireland, ⁹St. Vincent's University Hospital, Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, Dublin 4, Ireland, ¹⁰St Vincent's University Hospital, Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, St Vincent's University Hospital, Dublin 4, Dublin 4, Ireland
Background/Purpose: Giant cell arteritis (GCA) requires treatment with high dose corticosteroids. Many patients require chronic steroid therapy with associated significant side effects. There is a…
Abstract Number: 1958 • 2015 ACR/ARHP Annual Meeting
Diagnostic Value of Ultrasonography-Derived Signs in Giant Cell Arteritis: Literature Review and Meta-Analysis
Fanny BUSQUET¹, Léa Rouxel², Thomas Barnetche³ and Thierry Schaeverbeke⁴, ¹intern of hospital, BORDEAUX, France, ²intern of hospital, Bordeaux, France, ³PHD, bordeaux, France, ⁴department head, Bordeaux, France
Background/Purpose: Giant Cell Arteritis (GCA) is the most common form of systemic inflammatory vasculitis in elderly people, with prevalence still increasing, and for which there…
Abstract Number: 1960 • 2015 ACR/ARHP Annual Meeting
a Structured and Extensive Training Program on Vascular Ultrasound, Results in an Excellent Agreement Between Ultrasound and Temporal Artery Biopsy in the Diagnosis of Giant Cell Arteritis
Stavros Chrysidis¹, Ulrich Fredberg², Uffe Møller Døhn³, Tove Lorenzen⁴, Lene Terslev⁵, Knud Larsen⁶ and Andreas P Diamantopoulos⁷, ¹Department of Rheumatology, Hospital of Southwest Denmark, Esbjerg, Denmark, ²Department of Internal Medicine, Diagnostic Centre Region Hospital Silkeborg Denmark, Silkeborg, Denmark, ³Center for Rheumatology and Spine Diseases, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet - Glostrup, University of Copenhagen, Glostrup, Denmark, ⁴Diagnostic Centre, Region Hospital Silkeborg, Silkeborg, Denmark, ⁵Copenhagen University Hospital at Glostrup, Copenhagen, Denmark, ⁶otolaryngology, Southwest hospital, Esbjerg, Denmark, ⁷Rheumatology, Haugesund Hospital for Rheumatic Diseases, Haugesund, Norway
Background/Purpose: There is an increased use of vascular ultrasound (US) for diagnosing giant cell arteritis (GCA). Consequently, extensive and structured training of ultrasonographers performing vascular…
Abstract Number: 1962 • 2015 ACR/ARHP Annual Meeting
Inter-Rater Analysis of Ultrasound and Histological Findings in Patients with Suspected Giant Cell Arteritis
Raashid Luqmani¹, Ellen Lee², Surjeet Singh³, Michael Gillett², Wolfgang A. Schmidt⁴, Mike Bradburn², Bhaskar Dasgupta⁵, Andreas P Diamantopoulos⁶, Wulf Forrester-Barker⁷, William Hamilton⁸, Shauna Masters⁹, Brendan McDonald¹⁰, Eugene McNally⁷, Colin T. Pease¹¹, Jennifer Piper⁷, John Salmon¹², Allan Wailoo², Konrad Wolfe¹³, Andrew Hutchings¹⁴ and TABUL Sonographers Group and TABUL Pathologists Group, ¹Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²School of Health and Related Research, University of Sheffield, Sheffield, United Kingdom, ³1Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ⁴Medical Center for Rheumatology and Clinical Immunology Berlin-Buch, Immanuel Krankenhaus Berlin, Berlin, Germany, ⁵Rheumatology, Southend University Hospital, Essex, United Kingdom, ⁶Department of Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ⁷Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ⁸Primary Care, University of Exeter, Exeter, United Kingdom, ⁹Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Science, University of Oxford, Oxford, United Kingdom, ¹⁰Department of Neuropathology and Ocular Pathology, Oxford University Hospitals NHS Trust, Oxford, United Kingdom, ¹¹Rheumatology, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ¹²Ophthalmology, Oxford University Hospitals NHS Trust, Oxford, United Kingdom, ¹³Department of Pathology, Southend University Hospital, Essex, United Kingdom, ¹⁴Health Services Research Unit, London School of Hygiene and Tropical Medicine, London, United Kingdom
Background/Purpose: Ultrasound is emerging as an alternative test to performing a temporal artery biopsy in the diagnosis of giant cell arteritis (GCA). Little is known…
Abstract Number: 1965 • 2015 ACR/ARHP Annual Meeting
T Cell Activation, Proliferation and Differentiation Markers Lack Diagnostic Accuracy for Detecting Active GCA and PMR
Kornelis S.M. van der Geest¹, Wayel H. Abdulahad², Qi Wang², Mirjam Roffel², Gerda Horst², Abraham Rutgers², Annemieke M.H. Boots² and Elisabeth Brouwer², ¹Dept. of Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ²Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
Background/Purpose: The most important biomarker in GCA and PMR patients is increased erythrocytes sedimentation rate (ESR) and/ or increased serum level of C-reactive protein (CRP).…
Abstract Number: 1966 • 2015 ACR/ARHP Annual Meeting
Active PMR and GCA Is Associated with Changes in Monocyte Subset Composition
Qi Wang¹, Kornelis S.M. van der Geest², Wayel H. Abdulahad¹, Johanna Westra³, Annemieke M.H. Boots¹ and Elisabeth Brouwer¹, ¹Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ²Hanzeplein 1, Hpc: Aa21, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ³Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are two closely related syndromes affecting older people. Proinflammatory cytokine IL-6 is found increased in both…
Abstract Number: 1969 • 2015 ACR/ARHP Annual Meeting
Can We Predict the Relapse of Giant Cell Arteritis?
Alojzija Hocevar, Rok Ješe, Ziga Rotar, Sonja Praprotnik, Matija Tomšič and Saša Čučnik, Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia
Background/Purpose: Relapses during glucocorticoid (GC) tapering are frequent in giant cell arteritis (GCA). Anemia at the time of GCA diagnosis was a predictor of flare…
Abstract Number: 1970 • 2015 ACR/ARHP Annual Meeting
Incidence and Predictors of Thoracic Aortic Damage in Biopsy-Proven Giant Cell Arteritis: A Single-Institution Cohort Study
Matthew J. Koster¹, Cristian Labarca², Cynthia S. Crowson³, Eric L. Matteson¹ and Kenneth J. Warrington¹, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Rheumatology, Clinica Alemana Universidad del Desarrollo, Santiago, Chile, ³Health Sciences Research, Mayo Clinic, Rochester, MN
Background/Purpose: Patients with giant cell arteritis (GCA) are at an increased risk for aortic structural damage; however, the timing and predisposing characteristics for development of…
Abstract Number: 1971 • 2015 ACR/ARHP Annual Meeting
Healthcare Utilization and Direct Medical Costs of Giant Cell Arteritis
Matthew J. Koster¹, Sara J. Achenbach², Cynthia S. Crowson², Eric L. Matteson¹, Hilal Maradit Kremers² and Kenneth J. Warrington¹, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Department of Health Sciences Research, Mayo Clinic, Rochester, MN
Title: Healthcare Utilization and Direct Medical Costs of Giant Cell Arteritis Background/Purpose: Giant cell arteritis (GCA) is the most common systemic vasculitis in patients aged…
Abstract Number: 1974 • 2015 ACR/ARHP Annual Meeting
Do Patients with Giant Cell Arteritis Meet the 2011 United Kingdom Department of Health Guidance on Physical Activity?
Joanna Robson¹, Karolina Lada², Anne Miller³, Wilby Williamson¹, Julia Newton² and Raashid Luqmani⁴, ¹Rheumatology, University of Oxford, Oxford, United Kingdom, ²University of Oxford, Oxford, United Kingdom, ³Nuffield Orthopaedic Center, Oxford., Oxford, United Kingdom, ⁴Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom
Background/Purpose: Physical inactivity is the fourth leading risk factor for global mortality accounting for 6% of deaths. Patients with giant cell arteritis (GCA) are at…
Abstract Number: 1975 • 2015 ACR/ARHP Annual Meeting
Risk of Mortality of Patients with Giant Cell Arteritis: A Systematic Review and Meta-Analysis
Catherine Hill¹, Rachel Black², Johannes Nossent³, Carlee Ruediger⁴, Jem Ninan⁵ and Susan Lester⁶, ¹Rheumatology Unit, The Queen Elizabeth Hospital, Woodville, Australia, ²Medicine, University of Adelaide, Adelaide, Australia, ³Medicine, University of Western Australia, WA, Australia, ⁴Rheumatology, The Queen Elizabeth Hospital, Woodville, Australia, ⁵Rheumatology, Modbury Hospital, Modbury, Australia, ⁶Rheumatology, Basil Hetzel Institute, QEH, Woodville South, Australia
Background/Purpose: Previous studies of mortality associated with GCA have shown conflicting results.We conducted a systematic review and meta-analysis of observational studies to compare the mortality…
Abstract Number: 113 • 2015 ACR/ARHP Annual Meeting
Longitudinal, Incremental Direct Medical Costs of Giant Cell Arteritis for the First Five Years Following Diagnosis: A General Population-Based Cohort Study
Natalie McCormick¹, Carlo Marra² and J Antonio Avina-Zubieta³, ¹Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, ²Pharm Sciences, Univ of British Columbia, Vancouver, BC, Canada, ³Arthritis Research Canada / University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Giant cell arteritis (GCA) is the most common form of adult vasculitis, but estimates of the healthcare costs of GCA are extremely scarce. We…
Abstract Number: 1979 • 2015 ACR/ARHP Annual Meeting
Baseline Data on Patients Enrolled in a Randomized, Double-Blind Trial of Tocilizumab in Giant Cell Arteritis
Katie Tuckwell¹, Neil Collinson¹, Micki Klearman², Sophie Dimonaco¹, John H. Stone³ and on behalf of the GiACTA Investigators, ¹Roche Products Ltd., Welwyn Garden City, United Kingdom, ²Genentech, South San Francisco, CA, ³Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Background/Purpose: GiACTA, a randomized, double-blind, placebo-controlled trial of the interleukin-6 receptor alpha inhibitor tocilizumab (TCZ) in patients (pts) with giant cell arteritis (GCA), is the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].